Analytical Data
-
Gene name
NPFFR2
- Application
-
Alternative Names
/
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0PJM9
-
Expression Region
1-420aa
-
Molecular Weight
50.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NPFFR2, or Neuropeptide FF receptor 2, is a G-protein-coupled receptor (GPCR) known for its role in several physiological processes, including pain modulation, stress response, and neuroinflammation. Research indicates that NPFFR2 may be involved in the regulation of nociceptive pathways, potentially offering insights into pain management strategies. The receptor binds neuropeptides such as neuropeptide FF and neuropeptide AF, which can influence the analgesic effects and may interact with other signaling pathways in the central nervous system. Given the prevalence of chronic pain conditions and the limitations of current analgesics, understanding NPFFR2 could lead to novel therapeutic targets for pain relief. Furthermore, studies have suggested its involvement in various neuropsychiatric disorders, making it a promising candidate for drug development. Recombinant protein studies of NPFFR2 aim to elucidate its structural characteristics, ligand-binding affinities, and downstream signaling mechanisms, providing a foundation for future pharmacological interventions. The exploration of this receptor represents a critical frontier in neurobiology, with the potential to revolutionize approaches to treating complex pain syndromes and related disorders.
